Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 100

1.

Sorafenib in patients with hepatocellular carcinoma: 10 years of real life.

Rovesti G, Orsi G, Faloppi L, Gramantieri L, Silvestris N, Marisi G, Foschi F, Tamburini E, Andrikou K, Molinaro E, Riggi M, Scartozzi M, Cascinu S, Gardini AC.

Ann Oncol. 2019 Jul;30 Suppl 4:iv57. doi: 10.1093/annonc/mdz155.208. Epub 2019 Dec 4. No abstract available.

PMID:
32085214
2.

Multicentric prospective study of validation of angiogenesis-related gene polymorphisms in hepatocellular carcinoma patients treated with sorafenib: results of INNOVATE study.

Casadei Gardini A, Marisi G, Dadduzio V, Ielasi L, Vivaldi C, Rizzato M, Fornaro L, Lonardi S, Gramantieri L, Pecora I, Foschi F, Silvestris N, Fornari F, Orsi G, Rovesti G, Santini D, Zagonel V, Cascinu S, Scartozzi M.

Ann Oncol. 2019 Jul;30 Suppl 4:iv113. doi: 10.1093/annonc/mdz156.009. Epub 2019 Dec 4. No abstract available.

PMID:
32084979
3.

MiR-30e-3p influences tumor phenotype through MDM2/TP53 axis and predicts sorafenib resistance in hepatocellular carcinoma.

Gramantieri L, Pollutri D, Gagliardi M, Giovannini C, Quarta S, Ferracin M, Casadei-Gardini A, Callegari E, De Carolis S, Marinelli S, Benevento F, Vasuri F, Ravaioli M, Cescon M, Piscaglia F, Negrini M, Bolondi L, Fornari F.

Cancer Res. 2020 Feb 3. pii: canres.0472.2019. doi: 10.1158/0008-5472.CAN-19-0472. [Epub ahead of print]

PMID:
32015093
4.

Thyroid hormone inhibits hepatocellular carcinoma progression via induction of differentiation and metabolic reprogramming.

Kowalik MA, Puliga E, Cabras L, Sulas P, Petrelli A, Perra A, Ledda-Columbano GM, Morandi A, Merlin S, Orrù C, Sanchez-Martin C, Fornari F, Gramantieri L, Parri M, Rasola A, Bellomo SE, Sebastian C, Follenzi A, Giordano S, Columbano A.

J Hepatol. 2020 Jan 15. pii: S0168-8278(20)30009-X. doi: 10.1016/j.jhep.2019.12.018. [Epub ahead of print]

PMID:
31954205
5.

MicroRNAs in Animal Models of HCC.

Fornari F, Gramantieri L, Callegari E, Shankaraiah RC, Piscaglia F, Negrini M, Giovannini C.

Cancers (Basel). 2019 Dec 1;11(12). pii: E1906. doi: 10.3390/cancers11121906. Review.

6.

Animal Models of Hepatocellular Carcinoma Prevention.

Shankaraiah RC, Gramantieri L, Fornari F, Sabbioni S, Callegari E, Negrini M.

Cancers (Basel). 2019 Nov 14;11(11). pii: E1792. doi: 10.3390/cancers11111792. Review.

7.

Metformin prevents liver tumourigenesis by attenuating fibrosis in a transgenic mouse model of hepatocellular carcinoma.

Shankaraiah RC, Callegari E, Guerriero P, Rimessi A, Pinton P, Gramantieri L, Silini EM, Sabbioni S, Negrini M.

Oncogene. 2019 Nov;38(45):7035-7045. doi: 10.1038/s41388-019-0942-z. Epub 2019 Aug 13.

PMID:
31409896
8.

Role of SIRT-3, p-mTOR and HIF-1α in Hepatocellular Carcinoma Patients Affected by Metabolic Dysfunctions and in Chronic Treatment with Metformin.

De Matteis S, Scarpi E, Granato AM, Vespasiani-Gentilucci U, La Barba G, Foschi FG, Bandini E, Ghetti M, Marisi G, Cravero P, Gramantieri L, Cucchetti A, Ercolani G, Santini D, Frassineti GL, Faloppi L, Scartozzi M, Cascinu S, Casadei-Gardini A.

Int J Mol Sci. 2019 Mar 26;20(6). pii: E1503. doi: 10.3390/ijms20061503.

9.

Brivanib in combination with Notch3 silencing shows potent activity in tumour models.

Giovannini C, Salzano AM, Baglioni M, Vitale M, Scaloni A, Zambrano N, Giannone FA, Vasuri F, D'Errico A, Svegliati Baroni G, Bolondi L, Gramantieri L.

Br J Cancer. 2019 Mar;120(6):601-611. doi: 10.1038/s41416-018-0375-4. Epub 2019 Feb 15.

10.

MiR-122 Targets SerpinB3 and Is Involved in Sorafenib Resistance in Hepatocellular Carcinoma.

Turato C, Fornari F, Pollutri D, Fassan M, Quarta S, Villano G, Ruvoletto M, Bolondi L, Gramantieri L, Pontisso P.

J Clin Med. 2019 Feb 1;8(2). pii: E171. doi: 10.3390/jcm8020171.

11.

MicroRNA-Based Prophylaxis in a Mouse Model of Cirrhosis and Liver Cancer.

Callegari E, Domenicali M, Shankaraiah RC, D'Abundo L, Guerriero P, Giannone F, Baldassarre M, Bassi C, Elamin BK, Zagatti B, Ferracin M, Fornari F, Altavilla G, Blandamura S, Silini EM, Gramantieri L, Sabbioni S, Negrini M.

Mol Ther Nucleic Acids. 2019 Mar 1;14:239-250. doi: 10.1016/j.omtn.2018.11.018. Epub 2018 Dec 6.

12.

LncRNAs as novel players in hepatocellular carcinoma recurrence.

Gramantieri L, Baglioni M, Fornari F, Laginestra MA, Ferracin M, Indio V, Ravaioli M, Cescon M, De Pace V, Leoni S, Coadă CA, Negrini M, Bolondi L, Giovannini C.

Oncotarget. 2018 Oct 12;9(80):35085-35099. doi: 10.18632/oncotarget.26202. eCollection 2018 Oct 12.

13.

miR-199a-3p Modulates MTOR and PAK4 Pathways and Inhibits Tumor Growth in a Hepatocellular Carcinoma Transgenic Mouse Model.

Callegari E, D'Abundo L, Guerriero P, Simioni C, Elamin BK, Russo M, Cani A, Bassi C, Zagatti B, Giacomelli L, Blandamura S, Moshiri F, Ultimo S, Frassoldati A, Altavilla G, Gramantieri L, Neri LM, Sabbioni S, Negrini M.

Mol Ther Nucleic Acids. 2018 Jun 1;11:485-493. doi: 10.1016/j.omtn.2018.04.002. Epub 2018 Apr 12.

14.

Tissue miRNA 483-3p expression predicts tumor recurrence after surgical resection in histologically advanced hepatocellular carcinomas.

Vasuri F, Fittipaldi S, De Pace V, Gramantieri L, Bertuzzo V, Cescon M, Pinna AD, Fiorentino M, D'Errico A, Ravaioli M.

Oncotarget. 2018 Apr 3;9(25):17895-17905. doi: 10.18632/oncotarget.24860. eCollection 2018 Apr 3.

15.

Circulating miR-106b-3p, miR-101-3p and miR-1246 as diagnostic biomarkers of hepatocellular carcinoma.

Moshiri F, Salvi A, Gramantieri L, Sangiovanni A, Guerriero P, De Petro G, Bassi C, Lupini L, Sattari A, Cheung D, Veneziano D, Nigita G, Shankaraiah RC, Portolani N, Carcoforo P, Fornari F, Bolondi L, Frassoldati A, Sabbioni S, Colombo M, Croce CM, Negrini M.

Oncotarget. 2018 Feb 27;9(20):15350-15364. doi: 10.18632/oncotarget.24601. eCollection 2018 Mar 16.

16.

The epigenetically regulated miR-494 associates with stem-cell phenotype and induces sorafenib resistance in hepatocellular carcinoma.

Pollutri D, Patrizi C, Marinelli S, Giovannini C, Trombetta E, Giannone FA, Baldassarre M, Quarta S, Vandewynckel YP, Vandierendonck A, Van Vlierberghe H, Porretti L, Negrini M, Bolondi L, Gramantieri L, Fornari F.

Cell Death Dis. 2018 Jan 5;9(1):4. doi: 10.1038/s41419-017-0076-6.

17.

Corrigendum: Vidatox 30 CH has tumor activating effect in hepatocellular carcinoma.

Giovannini C, Baglioni M, Toaldo MB, Cescon M, Bolondi L, Gramantieri L.

Sci Rep. 2017 Dec 22;7:46920. doi: 10.1038/srep46920.

18.

MiR-199-3p replacement affects E-cadherin expression through Notch1 targeting in hepatocellular carcinoma.

Giovannini C, Fornari F, Dallo R, Gagliardi M, Nipoti E, Vasuri F, Coadă CA, Ravaioli M, Bolondi L, Gramantieri L.

Acta Histochem. 2018 Feb;120(2):95-102. doi: 10.1016/j.acthis.2017.12.004. Epub 2017 Dec 15.

PMID:
29249451
19.

miRNA Signature of Hepatocellular Carcinoma Vascularization: How the Controls Can Influence the Signature.

Fittipaldi S, Vasuri F, Bonora S, Degiovanni A, Santandrea G, Cucchetti A, Gramantieri L, Bolondi L, D'Errico A.

Dig Dis Sci. 2017 Sep;62(9):2397-2407. doi: 10.1007/s10620-017-4654-3. Epub 2017 Jun 21.

PMID:
28639131
20.

Vidatox 30 CH has tumor activating effect in hepatocellular carcinoma.

Giovannini C, Baglioni M, Baron Toaldo M, Cescon M, Bolondi L, Gramantieri L.

Sci Rep. 2017 Mar 21;7:44685. doi: 10.1038/srep44685. Erratum in: Sci Rep. 2017 Dec 22;7:46920.

21.

In Hepatocellular Carcinoma miR-221 Modulates Sorafenib Resistance through Inhibition of Caspase-3-Mediated Apoptosis.

Fornari F, Pollutri D, Patrizi C, La Bella T, Marinelli S, Casadei Gardini A, Marisi G, Baron Toaldo M, Baglioni M, Salvatore V, Callegari E, Baldassarre M, Galassi M, Giovannini C, Cescon M, Ravaioli M, Negrini M, Bolondi L, Gramantieri L.

Clin Cancer Res. 2017 Jul 15;23(14):3953-3965. doi: 10.1158/1078-0432.CCR-16-1464. Epub 2017 Jan 17.

22.

Targeting Notch3 in Hepatocellular Carcinoma: Molecular Mechanisms and Therapeutic Perspectives.

Giovannini C, Bolondi L, Gramantieri L.

Int J Mol Sci. 2016 Dec 28;18(1). pii: E56. doi: 10.3390/ijms18010056. Review.

23.

TP53/MicroRNA Interplay in Hepatocellular Carcinoma.

Pollutri D, Gramantieri L, Bolondi L, Fornari F.

Int J Mol Sci. 2016 Dec 2;17(12). pii: E2029. Review.

24.

Molecular and proteomic insight into Notch1 characterization in hepatocellular carcinoma.

Giovannini C, Minguzzi M, Genovese F, Baglioni M, Gualandi A, Ravaioli M, Milazzo M, Tavolari S, Bolondi L, Gramantieri L.

Oncotarget. 2016 Jun 28;7(26):39609-39626. doi: 10.18632/oncotarget.9203.

25.

Over-expression of the miR-483-3p overcomes the miR-145/TP53 pro-apoptotic loop in hepatocellular carcinoma.

Lupini L, Pepe F, Ferracin M, Braconi C, Callegari E, Pagotto S, Spizzo R, Zagatti B, Lanuti P, Fornari F, Ghasemi R, Mariani-Costantini R, Bolondi L, Gramantieri L, Calin GA, Sabbioni S, Visone R, Veronese A, Negrini M.

Oncotarget. 2016 May 24;7(21):31361-71. doi: 10.18632/oncotarget.8913.

26.

Metabolic reprogramming identifies the most aggressive lesions at early phases of hepatic carcinogenesis.

Kowalik MA, Guzzo G, Morandi A, Perra A, Menegon S, Masgras I, Trevisan E, Angioni MM, Fornari F, Quagliata L, Ledda-Columbano GM, Gramantieri L, Terracciano L, Giordano S, Chiarugi P, Rasola A, Columbano A.

Oncotarget. 2016 May 31;7(22):32375-93. doi: 10.18632/oncotarget.8632.

27.

The metabolic gene HAO2 is downregulated in hepatocellular carcinoma and predicts metastasis and poor survival.

Mattu S, Fornari F, Quagliata L, Perra A, Angioni MM, Petrelli A, Menegon S, Morandi A, Chiarugi P, Ledda-Columbano GM, Gramantieri L, Terracciano L, Giordano S, Columbano A.

J Hepatol. 2016 Apr;64(4):891-8. doi: 10.1016/j.jhep.2015.11.029. Epub 2015 Nov 30.

PMID:
26658681
28.

Circulating microRNAs, miR-939, miR-595, miR-519d and miR-494, Identify Cirrhotic Patients with HCC.

Fornari F, Ferracin M, Trerè D, Milazzo M, Marinelli S, Galassi M, Venerandi L, Pollutri D, Patrizi C, Borghi A, Foschi FG, Stefanini GF, Negrini M, Bolondi L, Gramantieri L.

PLoS One. 2015 Oct 28;10(10):e0141448. doi: 10.1371/journal.pone.0141448. eCollection 2015.

29.

c-MET receptor tyrosine kinase as a molecular target in advanced hepatocellular carcinoma.

Granito A, Guidetti E, Gramantieri L.

J Hepatocell Carcinoma. 2015 Apr 24;2:29-38. doi: 10.2147/JHC.S77038. eCollection 2015. Review.

30.

Suppression of p53 by Notch3 is mediated by Cyclin G1 and sustained by MDM2 and miR-221 axis in hepatocellular carcinoma.

Giovannini C, Minguzzi M, Baglioni M, Fornari F, Giannone F, Ravaioli M, Cescon M, Chieco P, Bolondi L, Gramantieri L.

Oncotarget. 2014 Nov 15;5(21):10607-20.

31.

MicroRNAs in liver cancer: a model for investigating pathogenesis and novel therapeutic approaches.

Callegari E, Gramantieri L, Domenicali M, D'Abundo L, Sabbioni S, Negrini M.

Cell Death Differ. 2015 Jan;22(1):46-57. doi: 10.1038/cdd.2014.136. Epub 2014 Sep 5. Review.

32.

Local hypothyroidism favors the progression of preneoplastic lesions to hepatocellular carcinoma in rats.

Frau C, Loi R, Petrelli A, Perra A, Menegon S, Kowalik MA, Pinna S, Leoni VP, Fornari F, Gramantieri L, Ledda-Columbano GM, Giordano S, Columbano A.

Hepatology. 2015 Jan;61(1):249-59. doi: 10.1002/hep.27399. Epub 2014 Nov 26.

PMID:
25156012
33.

p53/mdm2 feedback loop sustains miR-221 expression and dictates the response to anticancer treatments in hepatocellular carcinoma.

Fornari F, Milazzo M, Galassi M, Callegari E, Veronese A, Miyaaki H, Sabbioni S, Mantovani V, Marasco E, Chieco P, Negrini M, Bolondi L, Gramantieri L.

Mol Cancer Res. 2014 Feb;12(2):203-16. doi: 10.1158/1541-7786.MCR-13-0312-T. Epub 2013 Dec 9.

34.

Significance of serum and hepatic microRNA-122 levels in patients with non-alcoholic fatty liver disease.

Miyaaki H, Ichikawa T, Kamo Y, Taura N, Honda T, Shibata H, Milazzo M, Fornari F, Gramantieri L, Bolondi L, Nakao K.

Liver Int. 2014 Aug;34(7):e302-7. doi: 10.1111/liv.12429. Epub 2014 Jan 7.

PMID:
24313922
35.

The natural inhibitor of DNA topoisomerase I, camptothecin, modulates HIF-1α activity by changing miR expression patterns in human cancer cells.

Bertozzi D, Marinello J, Manzo SG, Fornari F, Gramantieri L, Capranico G.

Mol Cancer Ther. 2014 Jan;13(1):239-48. doi: 10.1158/1535-7163.MCT-13-0729. Epub 2013 Nov 19.

36.

Notch3 inhibition enhances sorafenib cytotoxic efficacy by promoting GSK3b phosphorylation and p21 down-regulation in hepatocellular carcinoma.

Giovannini C, Baglioni M, Baron Toaldo M, Ventrucci C, D'Adamo S, Cipone M, Chieco P, Gramantieri L, Bolondi L.

Oncotarget. 2013 Oct;4(10):1618-31.

37.

Anti-tumor activity of a miR-199-dependent oncolytic adenovirus.

Callegari E, Elamin BK, D'Abundo L, Falzoni S, Donvito G, Moshiri F, Milazzo M, Altavilla G, Giacomelli L, Fornari F, Hemminki A, Di Virgilio F, Gramantieri L, Negrini M, Sabbioni S.

PLoS One. 2013 Sep 12;8(9):e73964. doi: 10.1371/journal.pone.0073964. eCollection 2013.

38.

Role of microRNAs in hepatocellular carcinoma: a clinical perspective.

Callegari E, Elamin BK, Sabbioni S, Gramantieri L, Negrini M.

Onco Targets Ther. 2013 Sep 2;6:1167-78. doi: 10.2147/OTT.S36161. Review.

39.

miR-221 affects multiple cancer pathways by modulating the level of hundreds messenger RNAs.

Lupini L, Bassi C, Ferracin M, Bartonicek N, D'Abundo L, Zagatti B, Callegari E, Musa G, Moshiri F, Gramantieri L, Corrales FJ, Enright AJ, Sabbioni S, Negrini M.

Front Genet. 2013 Apr 25;4:64. doi: 10.3389/fgene.2013.00064. eCollection 2013.

40.

CDKN1C/P57 is regulated by the Notch target gene Hes1 and induces senescence in human hepatocellular carcinoma.

Giovannini C, Gramantieri L, Minguzzi M, Fornari F, Chieco P, Grazi GL, Bolondi L.

Am J Pathol. 2012 Aug;181(2):413-22. doi: 10.1016/j.ajpath.2012.04.019. Epub 2012 Jun 15.

PMID:
22705236
41.

Liver tumorigenicity promoted by microRNA-221 in a mouse transgenic model.

Callegari E, Elamin BK, Giannone F, Milazzo M, Altavilla G, Fornari F, Giacomelli L, D'Abundo L, Ferracin M, Bassi C, Zagatti B, Corrà F, Miotto E, Lupini L, Bolondi L, Gramantieri L, Croce CM, Sabbioni S, Negrini M.

Hepatology. 2012 Sep;56(3):1025-33. doi: 10.1002/hep.25747. Epub 2012 Jul 13.

PMID:
22473819
42.

In hepatocellular carcinoma miR-519d is up-regulated by p53 and DNA hypomethylation and targets CDKN1A/p21, PTEN, AKT3 and TIMP2.

Fornari F, Milazzo M, Chieco P, Negrini M, Marasco E, Capranico G, Mantovani V, Marinello J, Sabbioni S, Callegari E, Cescon M, Ravaioli M, Croce CM, Bolondi L, Gramantieri L.

J Pathol. 2012 Jul;227(3):275-85. doi: 10.1002/path.3995. Epub 2012 Apr 18.

PMID:
22262409
43.

Design, synthesis and biological evaluation of pyrazole derivatives as potential multi-kinase inhibitors in hepatocellular carcinoma.

Strocchi E, Fornari F, Minguzzi M, Gramantieri L, Milazzo M, Rebuttini V, Breviglieri S, Camaggi CM, Locatelli E, Bolondi L, Comes-Franchini M.

Eur J Med Chem. 2012 Feb;48:391-401. doi: 10.1016/j.ejmech.2011.12.031. Epub 2011 Dec 29.

PMID:
22227043
44.

From liver cirrhosis to HCC.

Bolondi L, Gramantieri L.

Intern Emerg Med. 2011 Oct;6 Suppl 1:93-8. doi: 10.1007/s11739-011-0682-8.

PMID:
22009618
45.

MicroRNA and hepatocellular carcinoma: biology and prognostic significance.

Milazzo M, Fornari F, Gramantieri L.

Minerva Gastroenterol Dietol. 2011 Sep;57(3):257-71. Review.

PMID:
21769076
46.

microRNA involvement in hepatocellular carcinoma.

Negrini M, Gramantieri L, Sabbioni S, Croce CM.

Anticancer Agents Med Chem. 2011 Jul;11(6):500-21. Review.

PMID:
21554203
47.

MicroRNA response to environmental mutagens in liver.

Elamin BK, Callegari E, Gramantieri L, Sabbioni S, Negrini M.

Mutat Res. 2011 Dec 1;717(1-2):67-76. doi: 10.1016/j.mrfmmm.2011.03.015. Epub 2011 Apr 14. Review.

PMID:
21514310
48.

Mutated beta-catenin evades a microRNA-dependent regulatory loop.

Veronese A, Visone R, Consiglio J, Acunzo M, Lupini L, Kim T, Ferracin M, Lovat F, Miotto E, Balatti V, D'Abundo L, Gramantieri L, Bolondi L, Pekarsky Y, Perrotti D, Negrini M, Croce CM.

Proc Natl Acad Sci U S A. 2011 Mar 22;108(12):4840-5. doi: 10.1073/pnas.1101734108. Epub 2011 Mar 7.

49.

Serum albumin-bound proteomic signature for early detection and staging of hepatocarcinoma: sample variability and data classification.

Camaggi CM, Zavatto E, Gramantieri L, Camaggi V, Strocchi E, Righini R, Merina L, Chieco P, Bolondi L.

Clin Chem Lab Med. 2010 Sep;48(9):1319-26. doi: 10.1515/CCLM.2010.248.

PMID:
20509833
50.

MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells.

Fornari F, Milazzo M, Chieco P, Negrini M, Calin GA, Grazi GL, Pollutri D, Croce CM, Bolondi L, Gramantieri L.

Cancer Res. 2010 Jun 15;70(12):5184-93. doi: 10.1158/0008-5472.CAN-10-0145. Epub 2010 May 25.

Supplemental Content

Loading ...
Support Center